A comprehensive and longitudinal cardiac magnetic resonance imaging study of the impact of coronary ischemia duration on myocardial damage in a highly translatable animal model.
CMR
adverse remodelling
ischemia duration
myocardial infarction
pig
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
01
08
2022
received:
22
06
2022
accepted:
18
08
2022
pubmed:
21
8
2022
medline:
15
12
2022
entrez:
20
8
2022
Statut:
ppublish
Résumé
We performed a comprehensive assessment of the effect of myocardial ischemia duration on cardiac structural and functional parameters by serial cardiac magnetic resonance (CMR) and characterized the evolving scar. CMR follow-up on the cardiac impact of time of ischemia in a closed-chest animal model of myocardial infarction with human resemblance is missing. Pigs underwent MI induction by occlusion of the left anterior descending (LAD) coronary artery for 30, 60, 90 or 120 min and then revascularized. Serial CMR was performed on day 3 and day 42 post-MI. CMR measurements were also run in a sham-operated group. Cellular and molecular changes were investigated. On day 3, cardiac damage and function were similar in sham and pigs subjected to 30 min of ischemia. Cardiac damage (oedema and necrosis) significantly increased from 60 min onwards. Microvascular obstruction was extensively seen in animals with ≥90 min of ischemia and correlated with cardiac damage. A drop in global systolic function and wall motion of the jeopardized segments was seen in pigs subjected to ≥60 min of ischemia. On day 42, scar size and cardiac dysfunction followed the same pattern in the animals subjected to ≥60 min of ischemia. Adverse left ventricular remodelling (worsening of both LV volumes) was only present in animals subjected to 120 min of ischemia. Cardiac fibrosis, myocyte hypertrophy and vessel rarefaction were similar in the infarcted myocardium of pigs subjected to ≥60 min of ischemia. No changes were observed in the remote myocardium. Sixty-minute LAD coronary occlusion already induces cardiac structural and functional alterations with longer ischemic time (120 min) causing adverse LV remodelling.
Sections du résumé
OBJECTIVES
OBJECTIVE
We performed a comprehensive assessment of the effect of myocardial ischemia duration on cardiac structural and functional parameters by serial cardiac magnetic resonance (CMR) and characterized the evolving scar.
BACKGROUND
BACKGROUND
CMR follow-up on the cardiac impact of time of ischemia in a closed-chest animal model of myocardial infarction with human resemblance is missing.
METHODS
METHODS
Pigs underwent MI induction by occlusion of the left anterior descending (LAD) coronary artery for 30, 60, 90 or 120 min and then revascularized. Serial CMR was performed on day 3 and day 42 post-MI. CMR measurements were also run in a sham-operated group. Cellular and molecular changes were investigated.
RESULTS
RESULTS
On day 3, cardiac damage and function were similar in sham and pigs subjected to 30 min of ischemia. Cardiac damage (oedema and necrosis) significantly increased from 60 min onwards. Microvascular obstruction was extensively seen in animals with ≥90 min of ischemia and correlated with cardiac damage. A drop in global systolic function and wall motion of the jeopardized segments was seen in pigs subjected to ≥60 min of ischemia. On day 42, scar size and cardiac dysfunction followed the same pattern in the animals subjected to ≥60 min of ischemia. Adverse left ventricular remodelling (worsening of both LV volumes) was only present in animals subjected to 120 min of ischemia. Cardiac fibrosis, myocyte hypertrophy and vessel rarefaction were similar in the infarcted myocardium of pigs subjected to ≥60 min of ischemia. No changes were observed in the remote myocardium.
CONCLUSION
CONCLUSIONS
Sixty-minute LAD coronary occlusion already induces cardiac structural and functional alterations with longer ischemic time (120 min) causing adverse LV remodelling.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13860Subventions
Organisme : Agencia Gestión Ayudas Universitarias Investigación: AGAUR
ID : 2016PROD00043
Organisme : Fundación Investigación Cardiovascular-Fundación Jesus Serra
Organisme : Generalitat of Catalunya-Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat
ID : 2017SGR1480
Organisme : Instituto de Salud Carlos III
ID : CIBERCV CB16/11/00411 to LB, TERCEL RD16/0011/018
Organisme : MCIN/AEI/10.13039/501100011033 and Fondo Europeo de Desarrollo Regional (FFEDER)
ID : PID2019-107160RB-I00 and PGC 2018-094025-B-I00
Organisme : Spanish Society of Cardiology
ID : FEC 2019 to MBP and FEC 2020 to GV
Informations de copyright
© 2022 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Simes RJ, Topol EJ, Holmes DR Jr, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I investigators. Circulation. 1995;91(7):1923-1928.
De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109(10):1223-1225.
Hausenloy DJ, Barrabes JA, Bøtker HE, et al. Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery. Basic Res Cardiol. 2016;111(6):70.
Heusch G. 25 years of remote ischemic conditioning: from laboratory curiosity to clinical outcome. Basic Res Cardiol. 2018;113(3):15.
Kleinbongard P, Skyschally A, Gent S, Pesch M, Heusch G. STAT3 as a common signal of ischemic conditioning: a lesson on "rigor and reproducibility" in preclinical studies on cardioprotection. Basic Res Cardiol. 2018;113(1):3.
Mendieta G, Ben-Aicha S, Gutiérrez M, et al. Intravenous statin administration during myocardial infarction compared with oral post-infarct administration. J Am Coll Cardiol. 2020;75(12):1386-1402.
Mendieta G, Ben-Aicha S, Casani L, Badimon L, Sabate M, Vilahur G. Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia. Basic Res Cardiol. 2019;115(1):2.
Díaz-Munoz R, Valle-Caballero MJ, Sanchez-Gonzalez J, et al. Intravenous metoprolol during ongoing STEMI ameliorates markers of ischemic injury: a METOCARD-CNIC trial electrocardiographic study. Basic Res Cardiol. 2021;116(1):45.
Ibanez B, Prat-González S, Speidl WS, et al. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. Circulation. 2007;115(23):2909-2916.
Davidson SM, Ferdinandy P, Andreadou I, et al. Multitarget strategies to reduce myocardial ischemia/reperfusion injury: JACC review topic of the week. J Am Coll Cardiol. 2019;73(1):89-99.
Vilahur G, Oñate B, Cubedo J, et al. Allogenic adipose-derived stem cell therapy overcomes ischemia-induced microvessel rarefaction in the myocardium: systems biology study. Stem Cell Res Ther. 2017;8(1):52.
Gao L, Gregorich ZR, Zhu W, et al. Large cardiac muscle patches engineered from human induced-pluripotent stem cell-derived cardiac cells improve recovery from myocardial infarction in swine. Circulation. 2018;137(16):1712-1730.
van der Velden J, Asselbergs FW, Bakkers J, et al. Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart. Cardiovasc Res. 2022:1-36. doi:10.1093/cvr/cvab370
Lecour S, Andreadou I, Bøtker HE, et al. IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST action. Basic Res Cardiol. 2021;116(1):52.
Bolli R, Ghafghazi S. Cell therapy needs rigorous translational studies in large animal models. J Am Coll Cardiol. 2015;66(18):2000-2004.
Lelovas PP, Kostomitsopoulos NG, Xanthos TT. A comparative anatomic and physiologic overview of the porcine heart. J Am Assoc Lab Anim Sci. 2014;53(5):432-438.
Naslund U, Haggmark S, Johansson G, Pennert K, Reiz S, Marklund SL. Effects of reperfusion and superoxide dismutase on myocardial infarct size in a closed chest pig model. Cardiovasc Res. 1992;26(2):170-178.
Fujiwara H, Matsuda M, Fujiwara Y, et al. Infarct size and the protection of ischemic myocardium in pig, dog and human. Jpn Circ J. 1989;53(9):1092-1097.
Reimer KA, Vander Heide RS, Richard VJ. Reperfusion in acute myocardial infarction: effect of timing and modulating factors in experimental models. Am J Cardiol. 1993;72(19):13G-21G.
Silvis MJM, van Hout GPJ, Fiolet ATL, et al. Experimental parameters and infarct size in closed chest pig LAD ischemia reperfusion models; lessons learned. BMC Cardiovasc Disord. 2021;21(1):171.
Ibanez B, Aletras AH, Arai AE, et al. Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel. J Am Coll Cardiol. 2019;74(2):238-256.
Stiermaier T, Jobs A, de Waha S, et al. Optimized prognosis assessment in ST-segment-elevation myocardial infarction using a cardiac magnetic resonance imaging risk score. Circ Cardiovasc Imaging. 2017;10(11):e006774.
Stone GW, Selker HP, Thiele H, et al. Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol. 2016;67(14):1674-1683.
Selker HP, Udelson JE, Ruthazer R, et al. Relationship between therapeutic effects on infarct size in acute myocardial infarction and therapeutic effects on 1-year outcomes: a patient-level analysis of randomized clinical trials. Am Heart J. 2017;188:18-25.
de Waha S, Patel MR, Granger CB, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. Eur Heart J. 2017;38(47):3502-3510.
Bonanad C, Monmeneu JV, Lopez-Lereu MP, et al. Prediction of long-term major events soon after a first ST-segment elevation myocardial infarction by cardiovascular magnetic resonance. Eur J Radiol. 2016;85(3):585-592.
Percie du Sert N, Ahluwalia A, Alam S, et al. Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 2020;18(7):e3000411.
Vilahur G, Gutiérrez M, Casani L, et al. P2Y12 antagonists and cardiac repair post-myocardial infarction: global and regional heart function analysis and molecular assessments in pigs. Cardiovasc Res. 2018;114(14):1860-1870.
Mendieta G, Ben-Aicha S, Casani L, Badimon L, Sabate M, Vilahur G. Intravenous statin administration during ischemia exerts cardioprotective effects. J Am Coll Cardiol. 2019;74(3):475-477.
Ortiz-Perez JT, Rodriguez J, Meyers SN, Lee DC, Davidson C, Wu E. Correspondence between the 17-segment model and coronary arterial anatomy using contrast-enhanced cardiac magnetic resonance imaging. JACC Cardiovasc Imaging. 2008;1(3):282-293.
López Lereu MP, Bodí V, Sanchis J, et al. Reliability of cardiac magnetic resonance imaging indicators of myocardial viability for predicting the recovery of systolic function after a first acute myocardial infarction with a patent culprit artery. Rev Esp Cardiol. 2004;57(9):826-833.
Vilahur G, Juan-Babot O, Pena E, Onate B, Casani L, Badimon L. Molecular and cellular mechanisms involved in cardiac remodeling after acute myocardial infarction. J Mol Cell Cardiol. 2011;50(3):522-533.
Heusch G, Skyschally A, Kleinbongard P. Translation, translation, translation: the need for large animal studies in cardioprotection research. Circ Res. 2018;123(8):931-933.
Heusch G. Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol. 2020;17(12):773-789.
Heusch G, Gersh BJ. Is cardioprotection salvageable? Circulation. 2020;141(6):415-417.
Bøtker HE, Hausenloy D, Andreadou I, et al. Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol. 2018;113(5):39.
Heusch G. Cardioprotection research must leave its comfort zone. Eur Heart J. 2018;39(36):3393-3395.
Shen YT, Fallon JT, Iwase M, Vatner SF. Innate protection of baboon myocardium: effects of coronary artery occlusion and reperfusion. Am J Phys. 1996;270(5 Pt 2):H1812-H1818.
Sasayama S. Effect of coronary collateral circulation on myocardial ischemia and ventricular dysfunction. Cardiovasc Drugs Ther. 1994;8(Suppl 2):327-334.
Kloner RA, Ellis SG, Lange R, Braunwald E. Studies of experimental coronary artery reperfusion. Effects on infarct size, myocardial function, biochemistry, ultrastructure and microvascular damage. Circulation. 1983;68(2 Pt 2):I8-I15.
Hale SL, Kloner RA. Effect of early coronary artery reperfusion on infarct development in a model of low collateral flow. Cardiovasc Res. 1987;21(9):668-673.
Naslund U, Haggmark S, Johansson G, Marklund SL, Reiz S. A closed-chest myocardial occlusion-reperfusion model in the pig: techniques, morbidity and mortality. Eur Heart J. 1992;13(9):1282-1289.
Hedstrom E, Engblom H, Frogner F, et al. Infarct evolution in man studied in patients with first-time coronary occlusion in comparison to different species-implications for assessment of myocardial salvage. J Cardiovasc Magn Reson. 2009;11:38.
Bouisset F, Gerbaud E, Bataille V, et al. Percutaneous myocardial revascularization in late-presenting patients with STEMI. J Am Coll Cardiol. 2021;78(13):1291-1305.
Heusch G. Critical issues for the translation of cardioprotection. Circ Res. 2017;120(9):1477-1486.
Van Allen NR, Krafft PR, Leitzke AS, Applegate RL 2nd, Tang J, Zhang JH. The role of volatile anesthetics in cardioprotection: a systematic review. Med Gas Res. 2012;2(1):22.
Niccoli G, Montone RA, Ibanez B, et al. Optimized treatment of ST-elevation myocardial infarction. Circ Res. 2019;125(2):245-258.
Bulluck H, Hammond-Haley M, Weinmann S, Martinez-Macias R, Hausenloy DJ. Myocardial infarct size by CMR in clinical cardioprotection studies: insights from randomized controlled trials. JACC Cardiovasc Imaging. 2017;10(3):230-240.
Fernández-Jiménez R, Barreiro-Pérez M, Martin-García A, et al. Dynamic edematous response of the human heart to myocardial infarction: implications for assessing myocardial area at risk and salvage. Circulation. 2017;136(14):1288-1300.
Fernández-Jiménez R, Sánchez-González J, Agüero J, et al. Myocardial edema after ischemia/reperfusion is not stable and follows a bimodal pattern: imaging and histological tissue characterization. J Am Coll Cardiol. 2015;65(4):315-323.
Horneffer PJ, Healy B, Gott VL, Gardner TJ. The rapid evolution of a myocardial infarction in an end-artery coronary preparation. Circulation. 1987;76(5 Pt 2):V39-V42.
Hjortbak MV, Olesen KKW, Seefeldt JM, et al. Translation of experimental cardioprotective capability of P2Y12 inhibitors into clinical outcome in patients with ST-elevation myocardial infarction. Basic Res Cardiol. 2021;116(1):36.
Francis R, Chong J, Ramlall M, et al. Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Basic Res Cardiol. 2021;116(1):59.
Heusch G. Coronary microvascular obstruction: the new frontier in cardioprotection. Basic Res Cardiol. 2019;114(6):45.
McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion. Circulation. 1986;74(4):693-702.
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289(2):194-202.
Reindl M, Reinstadler SJ, Tiller C, et al. Prognosis-based definition of left ventricular remodeling after ST-elevation myocardial infarction. Eur Radiol. 2019;29(5):2330-2339.
Legallois D, Hodzic A, Alexandre J, et al. Definition of left ventricular remodelling following ST-elevation myocardial infarction: a systematic review of cardiac magnetic resonance studies in the past decade. Heart Fail Rev. 2022;27(1):37-48.
Campbell SE, Gerdes AM, Smith TD. Comparison of regional differences in cardiac myocyte dimensions in rats, hamsters, and Guinea pigs. Anat Rec. 1987;219(1):53-59.
Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400-423.
Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39(30):2780-2792.
Jeong EM, Dudley SC Jr. Diastolic dysfunction. Circ J. 2015;79(3):470-477.
Kleinbongard P, Botker HE, Ovize M, Hausenloy DJ, Heusch G. Co-morbidities and co-medications as confounders of cardioprotection-Does it matter in the clinical setting? Br J Pharmacol. 2020;177(23):5252-5269.
Andreadou I, Schulz R, Badimon L, et al. Hyperlipidaemia and cardioprotection: animal models for translational studies. Br J Pharmacol. 2020;177(23):5287-5311.
Vilahur G, Gutiérrez M, Casaní L, et al. Hypercholesterolemia abolishes high-density lipoprotein-related cardioprotective effects in the setting of myocardial infarction. J Am Coll Cardiol. 2015;66(21):2469-2470.
Lazou A, Ikonomidis I, Bartekova M, et al. Chronic inflammatory diseases, myocardial function and cardioprotection. Br J Pharmacol. 2020;177(23):5357-5374.
Andreadou I, Tsoumani M, Vilahur G, et al. PCSK9 in myocardial infarction and cardioprotection: importance of lipid metabolism and inflammation. Front Physiol. 2020;11:602497.